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Abstract
Background: Prokineticin 2 (PK2) is a secreted protein and causes potent hyperalgesia in vivo, and is therefore
considered to be a new pronociceptive mediator. However, the molecular targets responsible for the
pronociceptive effects of PK2 are still poorly understood. Here, we have found that PK2 potentiates the activity of
acid-sensing ion channels in the primary sensory neurons.
Methods: In the present study, experiments were performed on neurons freshly isolated from rat dorsal root
ganglion by using whole-cell patch clamp and voltage-clamp recording techniques.
Results: PK2 dose-dependently enhanced proton-gated currents with an EC50 of 0.22 ± 0.06 nM. PK2 shifted the
proton concentration-response curve upwards, with a 1.81 ± 0.11 fold increase of the maximal current response. PK2
enhancing effect on proton-gated currents was completely blocked by PK2 receptor antagonist. The potentiation
was also abolished by intracellular dialysis of GF109203X, a protein kinase C inhibitor, or FSC-231, a protein
interacting with C-kinase 1 inhibitor. Moreover, PK2 enhanced the acid-evoked membrane excitability of rat dorsal
root ganglion neurons and caused a significant increase in the amplitude of the depolarization and the number of
spikes induced by acid stimuli. Finally, PK2 exacerbated nociceptive responses to the injection of acetic acid in rats.
Conclusion: These results suggest that PK2 increases the activity of acid-sensing ion channels via the PK2 receptor
and protein kinase C-dependent signal pathways in rat primary sensory neurons. Our findings support that PK2 is a
proalgesic factor and its signaling likely contributes to acidosis-evoked pain by sensitizing acid-sensing ion
channels.
Keywords: Acid-sensing ion channel, Dorsal root ganglion neuron, Neuronal excitability, Pain, Prokineticin 2,
Proton-gated current
Background
It is well known that tissue acidosis produces pain. For in-
stance, direct application of an acidic solution into the skin
induces non-adapting pain [1,2]. Tissue acidosis occurs in
a variety of pathological states, including inflammation, is-
chemia, tissue injury and tumor development [3,4]. The
local drop in pH is detected by acid-sensing ion channels
(ASICs) on peripheral nociceptors and plays an important
role in pathological pain in these conditions [5]. To date,
seven subunits of ASICs (1a, 1b1, 1b2, 2a, 2b, 3 and 4)
encoded by four genes have been identified [6]. All ASICs
except ASIC4 are present in primary sensory neurons [7,8].
ASICs are activated by extracellular protons and contribute
to pain caused by tissue acidosis. Increasing evidence sug-
gests that ASICs are involved in inflammatory and neuro-
pathic pain [9-11].
Prokineticin 2 (PK2) is a multifunctional secreted
regulatory peptide that signals through two G protein-
coupled receptors termed prokineticin receptors 1 and 2
(PKR1 and PKR2) [12-14]. Emerging evidence indicates
that PK2 is also associated with pain perception.
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Intraplantar injection of PK2 and Bv8, the frog homolog
of mammalian PK2, causes a strong and localized
hyperalgesia by reducing the nociceptive thresholds to
thermal, mechanical and chemical stimuli [15-17]. PK2
is highly expressed by neutrophils and other inflamma-
tory cells and releases in inflamed tissues, thus it is
considered as a new pronociceptive mediator [18].
Genetic studies have confirmed the critical involve-
ment of PK2 signaling in pain perception, particularly
via PKR1 activation. Mice lacking either PK2 or PKR1
genes displayed a significant reduction in nociception
induced by noxious heat and various chemical stimuli
such as capsaicin, protons and formalin [15,19].
Recently, Watson et al. found that increased PK2 expres-
sion in gut inflammation likely contributes to visceral
pain [20]. It has been shown that PKR1 and PKR2 are
present in nociceptive primary sensory neurons [15,17].
Calcium image studies have revealed that the majority of
dorsal root ganglia (DRG) neurons are activated by PK2
[15,17]. Thus, PK2 may act directly on sensory neurons.
It has been shown that Bv8 sensitizes transient receptor
potential vanilloid receptor-1 (TRPV1) and potentiates
the inward current activated by capsaicin in DRG
neurons [21]. These results demonstrate a positive inter-
action between the PKRs and the vanilloid receptors.
However, blocking TRPV1 pathway reduces but does
not abolish Bv8-induced hyperalgesia, indicating that
Bv8-induced pain sensitization also involves other
signaling pathways [19,22]. In this study, we show that
PK2 potentiates the activity of ASICs in the rat DRG
sensory neurons.
Methods
Isolation of the dorsal root ganglia neurons
The experimental protocol was approved by the animal
research ethics committee of Hubei University of
Science and Technology. All procedures conformed to
international guidelines on the ethical use of animals,
and every effort was made to minimize the number of
animals used and their suffering. Two- to three-week old
Sprague–Dawley male rats were anesthetized with ethyl
ether and then decapitated. The DRGs were taken out
and transferred immediately into DMEM (Sigma-
Aldrich, St. Louis, MO, US) at pH 7.4. After the removal
of the surrounding connective tissues, the DRGs were
minced with fine spring scissors and the ganglion
fragments were placed in a flask containing 5 mL of
DMEM in which trypsin (type II-S, Sigma) 0.5 mg/mL,
collagenase (type I-A, Sigma) 1.0 mg/mL and DNase
(type IV, Sigma) 0.1 mg/mL had been dissolved, and
incubated at 35 °C in a shaking water bath for 25 to
30 min. Soybean trypsin inhibitor (type II-S, Sigma)
1.25 mg/mL was then added to stop trypsin digestion.
Dissociated neurons were placed into a 35 mm Petri dish
and kept for at least another 60 min before electro-
physiological recordings. The neurons selected for
electrophysiological experiment were 15 to 35 μm in
diameter.
Electrophysiological recordings
Whole-cell patch clamp and voltage-clamp recordings
were carried out at room temperature (22 to 25 °C)
using a MultiClamp-700B amplifier and Digidata-1440A
A/D converter (Axon Instruments, Foster City. CA,
USA). Recording pipettes were pulled using a Sutter P-
97 puller (Sutter Instruments, Novato, CA, USA). The
micropipettes were filled with internal solution contain-
ing KCl 140 mM, MgCl2 2.5 mM, HEPES 10 mM, EGTA
11 mM and ATP 5 mM; its pH was adjusted to 7.2 with
KOH and osmolarity was adjusted to 310 mOsm/L with
sucrose. Cells were bathed in an external solution
containing NaCl 150 mM, KCl 5 mM, CaCl2 2.5 mM,
MgCl2 2 mM, HEPES 10 mM and d-glucose 10 mM; its
osmolarity was adjusted to 330 mOsm/L with sucrose
and pH to 7.4. The resistance of the recording pipette
was in the range of 3 to 6 MΩ. A small patch of
membrane underneath the tip of the pipette was aspi-
rated to form a gigaseal and then negative pressure was
applied to rupture it, thus establishing a whole-cell
configuration. The adjustment of capacitance compensa-
tion and series resistance compensation was done before
recording the membrane currents. The membrane
voltage was maintained at −60 mV in all voltage-clamp
experiments unless otherwise specified. Current-clamp
recordings were obtained by switching to current-clamp
mode after a stable whole-cell configuration was formed
in voltage-clamp mode. Only cells with a stable resting
membrane potential (more negative than −−50 mV)
were used in the study. Signals were sampled at 10 to
50 kHz and filtered at 2 to 10 kHz, and the data were
stored in compatible PC computer for off-online analysis
using the pCLAMP 10 acquisition software (Axon
Instruments).
Drug application
Drugs used in the experiments include: HCl, PK2 and
PK2 receptor antagonist (PKRA; Zhou laboratory,
University of California, Irvine, CA, USA), amiloride
(Sigma), capsazepine (RBI, Natick, MA, US) and tetro-
dotoxin (TTX; Sigma). All drugs were dissolved daily in
the external solution just before use and held in a linear
array of fused silica tubes (outside diameter/inside
diameter = 500 μm/200 μm) connected to a series of
independent reservoirs. The application pipette tips were
positioned approximately 30 μm away from the recorded
neurons. The application of each drug was driven by
gravity and controlled by the corresponding valve, and
rapid solution exchange could be achieved within about
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100 ms by shifting the tubes horizontally with a PC-
controlled micromanipulator. Cells were constantly
bathed in normal external solution flowing from one
tube connected to a larger reservoir between drug appli-
cations. In some experiments where GF109203X (RBI)
and FSC-231 (Gether Lab, University of Copenhagen,
DK-2200 Copenhagen, Denmark) were applied for intra-
cellular dialysis, they were dissolved in the internal
solution before use. To functionally characterize ASIC
activity, we used capsazepine (10 μM) to block TRPV1
in this study [23].
Nociceptive behavior induced by acetic acid in rats
Sprague–Dawley male rats (3 to 4 weeks old) were kept
with a 12 h light/dark cycle and with ad libitum access to
food and water. Animals were placed in a 30× 30× 30 cm3
Plexiglas chamber and allowed to habituate for at least
30 min before nociceptive behavior experiments. After
pretreatment with 10 μL capsazepine (100 μM), a double-
blind experiment was carried out. Twenty microliters of
acetic acid solution (0.6%) together with 20 μL external so-
lution, amiloride, PK2 and/or PKRA were coded, and the
other experimenters subcutaneously administered them
into the dorsal face of the hind paw using a 30 gauge nee-
dle connected to a 100 μL Hamilton syringe. Nociceptive
behavior (that is, number of flinches) was counted over a
5 min period starting immediately after the injection
[9,24].
Data analysis
Data were statistically compared using the Student’s t-test
or analysis of variance (ANOVA), followed by Bonferroni’s
post hoc test. Statistical analysis of concentration-response
data was performed using nonlinear curve-fitting program
ALLFIT. Data are expressed as mean± standard error of
the mean (SEM).
Results
Prokineticin 2 enhanced proton-gated currents in rat
dorsal root ganglia neurons
All current measurements in this study were done in small
and medium diameter (15 to 35 μm) acutely isolated DRG
neurons of adult rats. To functionally characterize ASIC
currents, we measured proton-gated currents in the pres-
ence of the TRPV1 inhibitor, capsazepine (10 μM), in the
whole-cell patch-clamp configuration [23]. In the present
study, the majority of DRG neurons (68.9%, 91 out of 132)
examined were sensitive to extracellular application of a
pH 5.5 solution for 5 s with an inward current (IpH5.5).
Under our experimental conditions, proton-induced cur-
rents could be separated into the following three classes
on the basis of their amplitudes and inactivation time
courses: a slow-inactivating transient inward current fol-
lowed by a sustained component was present in 59.3% (54
out of 91) of neurons (Figure 1A); a fast-inactivating tran-
sient current was present in 12.1% (11 out of 91) of neu-
rons (Figure 1B); and a sustained current with a small
Figure 1 Potentiation of proton-gated currents by prokineticin 2 in rat dorsal root ganglia neurons. Three types of proton-induced
currents were recorded in DRG neurons. Example traces of a (A) slow-inactivating current, (B) fast-inactivating current and (C) sustained current.
All three types of proton-induced currents could be inhibited by 20 μM amiloride, a broad-spectrum ASIC channel blocker. Pre-application of PK2
increased the peak phases of all three types of proton-induced currents. Proton-induced currents were evoked by extracellular application of a pH
5.5 solution for 5 s in the presence of the TRPV1 inhibitor capsazepine (10 μm). The pretreatment time for PK2 (1 nM) was 60 s. ASIC: acid-sensing
ion channels; DRG: dorsal ganglia root; PK2: prokineticin 2; TRPV1: transient receptor potential vanilloid receptor-1.
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transient phase in 28.6% (26 out of 91) of cells (Figure
1 C). The maximum amplitude of the slow- and rapid-
inactivating transient current was at least three times
greater than that of the sustained current. The transient
currents could be clearly divided into two groups on the
basis of their inactivation time constants. The slow-
inactivating transient current had a mean inactivation time
constant of 1,845.1 ± 192.6 ms, whereas the rapid-
inactivating current had a shorter inactivation time
constant (452.5± 68.3 ms, P <0.001). We established
objective criteria for the distinction of these current types.
Time constants of inactivation <800 ms were classified as
rapid-inactivating current, while those >800 ms were clas-
sified as slow-inactivating current. In the presence of the
TRPV1 inhibitor, capsazepine (10 μm), ASICs are the only
channels known to mediate transient proton-gated cur-
rents, since all observed transient currents could be inhib-
ited by 20 μM amiloride, a broad-spectrum ASIC channel
blocker. Therefore, we considered them as ASIC currents.
Application of PK2 (1 nM) 60 s prior to acid solution
enhanced IpH5.5 in the majority of the neurons sensitive
to acid stimuli (72.5%, 66 out of 91; Figure 1). The
enhanced effect of PK2 was observed in all three types
of proton-evoked currents (Figure 1). The amplitude of
peak phase of slow-inactivating current increased to
187.1 ± 11.8% of that before application of PK2 (n = 7, P
<0.01), the rapid-inactivating current to 181.4 ± 13.9%
(n = 7, P <0.01) and the sustained current to
179.4 ± 14.6% (n = 7, P <0.01). Since PK2 showed similar
modification on all three types of currents, we pooled
data in further experiments.
We next investigated whether the potentiation of
proton-gated currents was dependent on the concentra-
tions of PK2. Figure 2A shows that the amplitudes of
IpH5.5 increased when the concentrations of PK2
increased from 0.1 nM to 1 nM. Figure 2B shows the
dose–response curve for PK2 in the potentiation of
























Figure 2 Concentration-dependent potentiation of proton-gated currents by prokineticin 2. (A) Sequential current traces illustrate the
potentiation of proton-induced currents by different concentration of PK2 on a DRG neuron. Proton-gated currents were elicited by application
of pH 5.5 for 5 s durations. The pretreatment time for PK2 was 60 s. (B) PK2 concentration-dependently potentiated proton-gated currents (IpH5.5).
Each point represents the mean± SEM of 6 to 10 neurons. DRG: dorsal ganglia root; PK2: prokineticin 2.
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(95.6 ± 16.8%, n = 7) at a concentration of 3 nM. The
half-maximal response (EC50) value of the dose–re-
sponse curve for PK2 was 0.22 ± 0.06 nM (Figure 2B).
Blockade of prokineticin 2-induced potentiation of
proton-gated currents by prokineticin 2 receptor
antagonist
To verify whether the potentiation of proton-gated
currents by PK2 was mediated by a PK2 receptor, we used
a small-molecule PKRA that blocks both PKR1 and PKR2
[25]. The effect of PKRA on potentiation of proton-gated
currents by PK2 was examined. The potentiation of IpH5.5
by pretreatment with PK2 (1 nM) was almost completely
reversed by the addition of 10 nM PKRA (Figure 3, P
<0.01, one-way ANOVA followed by Bonferroni’s post
hoc test, n = 7). Moreover, PKRA itself had no effect on
IpH5.5 (data not shown).
Concentration-response relationship for proton-gated
currents with and without pretreatment of prokineticin 2
We then investigated whether the potentiation of PK2
was dependent on the concentrations of proton. Figure
4A shows that currents evoked by different pHs were
enhanced by PK2. First, pretreatment of PK2 shifted the
concentration-response curve to protons upwards, as
indicated by a 1.81 ± 0.11 fold increase of the maximal
current response to protons when PK2 was pre-applied.
However, the slopes or Hill coefficients of those two
curves were essentially similar (n = 1.29 in the absence of
PK2 versus n = 1.31 in the presence of PK2; P >0.1,
Bonferroni’s post hoc test). Second, the EC50 values of
both curves had no statistical difference (pH 5.96 ± 0.08
with PK2 pretreatment versus pH 5.92 ± 0.06 without
PK2 pretreatment; P >0.1, Bonferroni’s post hoc test).
Third, the threshold pH value was essentially the same.
Intracellular mechanisms underlying the potentiation of
proton-gated currents by prokineticin 2 signaling
PK2 receptors belong to the Gq-protein-coupled receptor
family, and the activation of these receptors leads to a cas-
cade of events that activate the protein kinase C (PKC) sys-
tem [21,26]. To further explore whether the potentiation of
IpH by PK2 is mediated through the PKC signaling path-
way, a selective PKC inhibitor, GF109203 X, was applied
internally to DRG neurons through recording patch pip-
ettes. In the control experiments, each neuron was patch-
clamped twice with the normal internal solution. The in-
crease of IpH5.5 induced by PK2 in the first patch experi-
ment was 85.6± 10.7% and in the second was 81.2 ± 12.4%
(n=7, P >0.1, paired t-test). In contrast, the potentiation
of IpH5.5 induced by PK2 was abolished when examined at
30 min after intracellular dialysis with 2 μM GF109203 X
(19.9 ± 5.9%, n=8, P <0.01, post hoc Bonferroni’s test; Fig-
ure 5). Phorbol 12-myristate 13-acetate (PMA, 10 μM), a
membrane-permeable activator of PKC, also produced a
102.9 ± 13.2% enhanced effect on IpH5.5 when it was pre-
























Figure 3 Blockade of prokineticin 2-induced potentiation of proton-gated currents by prokineticin 2 receptor antagonist. The current
traces in (A) and the bar graph in (B) show that the potentiation of IpH5.5 by PK2 (1 nM) pre-applied alone was abolished by the co-application of
PK2 and PKRA (10 nM), a PK2 receptor antagonist. **P <0.01, one-way analysis of variance followed by post hoc Bonferroni’s test, n = 7. PKRA:
prokineticin 2 receptor antagonist; PK2: prokineticin 2.
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applied externally to DRG neurons for 60 s. The result
indicated that PKC activators can mimic the effect of PK2.
Moreover, PK2 (1 nM) only caused a 7.2 ± 8.2% enhanced
effect on IpH5.5 after FSC-231 (50 μM), a protein interacting
with C-kinase 1 (PICK1) inhibitor, was applied internally to
DRG neurons (n=7, P <0.01, post hoc Bonferroni’s test;
Figure 5). Re-patch and intracellular dialysis did not signifi-
cantly alter the amplitude of IpH5.5. These results indicated
that the potentiation of IpH induced by PK2 was blocked
by the PKC inhibitor and PICK1 inhibitor.
Effect of prokineticin 2 on proton-induced membrane
excitability of rat dorsal root ganglia neurons
Further experiments were performed in the presence of
capsazepine (10 μM) and TTX (1 μM) to block TRPV1
and Na+ channel-mediated action potentials, respect-
ively. It was shown that TTX is not effective in blocking
the proton-gated currents, although it blocks the major-
ity of voltage-gated Na+ currents [27]. A pH 6.0 acid
stimulus induced an inward current in a DRG neuron
tested with voltage-clamp recording, whereas it also
produced a depolarization of the resting membrane
potential in the same cell under current-clamp recording
(I = 0 pA) conditions (Figure 6A). In this particular cell,
pre-application of 1 nM PK2 for 60 s increased this
acid-evoked depolarization of the membrane potential
(Figure 6A). After exposure to pH 6.0, membrane poten-
tial depolarized from 65.1 ± 4.3 mV to 56.5 ± 4.0 mV. In
contrast, PK2 increased the magnitude of acid-induced
depolarization from 8.6 ± 0.7 mV to 13.4 ± 1.4 mV
(paired t-test, P <0.05, n = 6). After a 20 min washout of
PK2, the acid-evoked depolarization of membrane
potential recovered to control condition (9.3 ± 1.4 mV,
paired t-test, P >0.1, compared with 8.6 ± 0.7 mV of
control condition, n = 6; Figure 6A and C).
In the presence of the TRPV1 inhibitor, capsazepine
(10 μM), a steep pH drop from 7.4 to 5.5 could trigger
bursts of action potentials under current-clamp condi-
tions in a neuron tested, while the whole-cell current


























Figure 4 Concentration-response relationship for protons with or without the pre-application of prokineticin 2. (A) Sequential currents
evoked by different pHs in the absence or presence of PK2. (B) The concentration-response curves for protons with or without PK2 (1 nM) pre-
application. Each point represents the mean± SEM of 7 to 11 neurons. All current values were normalized to the current response induced by pH
4.5 applied alone (marked with asterisk). The curves shown are a best fit of the data to the logistic equation I= Imax/[1 + (EC50/C)
n], where C is the
concentration of protons, I is the normalized current response value, EC50 is the proton concentration that produced half the maximal current
response to protons, and n is the Hill coefficient. The curves for protons without and with PK2 pre-application were drawn according to the
equation described above (the Hill coefficients are 1.29 with PK2 pre-application and 1.31 without). The pretreatment of PK2 shifts the
concentration-response curve for protons upwards. PK2: prokineticin 2; SEM: standard error of the mean.
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voltage-clamp recording (Figure 6B). The mean number
of spikes was 1.5 ± 0.7 during exposure to pH 5.5 for 5 s
in the six neurons tested (Figure 6D). Similarly, the pre-
application of PK2 (1 nM, 60 s) increased the acid-
induced spiking, and the mean number of spikes
increased to 4.2 ± 0.8 (paired t-test, P <0.05, n = 6). After
a 20 min washout with PK2, the mean number of spikes
evoked by acid was 1.9 ± 0.9, which was not significantly
different from the control condition (1.5 ± 0.7, paired t-
test, P >0.1, n = 6; Figure 6B and D). These results
indicated that PK2 increased proton-induced membrane
excitability of rat DRG neurons.
Effect of prokineticin 2 on nociceptive responses to
injection of acetic acid in rats
Acetic acid elicits an intense flinch/shaking response in
rats [9,24]. The flinch response mainly occurs 0 to 5 min
after intraplantar injection of the acetic acid. In the
present study, intraplantar injection of 20 μL acetic acid
solution (0.6%) in the presence of the TRPV1 inhibitor
capsazepine (100 μM) caused an intense flinch/shaking
response, and treatment of 200 μM amiloride potently
blocked acid-evoked pain (data not shown). Figure 7
shows that the application of PK2 dose-dependently
exacerbated flinching behavior induced by acetic acid.
The number of flinches increased from 11.5 ± 1.5 in
control conditions to 20.3 ± 2.9 with 3 nM PK2 pretreat-
ment (P <0.01, post hoc Bonferroni’s test, n = 10). The
enhancing effect of PK2 on acetic acid-induced pain
behavior failed to exert when PKRA (10 nM, a PK2
receptor antagonist) was co-injected together with 3 nM
PK2. The number of flinches induced by acetic acid
(13.1 ± 0.6) was not significantly different from that of
the control conditions (P >0.1, post hoc Bonferroni’s
test, n = 10). Moreover, intraplantar injection of PK2 or
PKRA by themselves did not elicit an obvious flinch/
shaking response, and the number of flinches were
0.7 ± 0.5 and 0.6 ± 0.3, respectively. These results indicate
that PK2 contributes to acidosis-evoked pain.
Discussion
The present study demonstrated that PK2 enhanced the
activity of ASICs via the PK2 receptor in freshly isolated
rat DRG neurons. PK2 increased the amplitude of ASIC
currents, the number of spike discharges induced by acid
stimuli and nociceptive responses to the injection of
acetic acid. We further showed that the PKC-dependent
signal pathway likely underlies intracellular mechanisms
in enhancing ASIC activity by PK2.
In agreement with previous studies, extracellular
application of acid solution was found to evoke three dif-
ferent currents in DRG neurons: slow-inactivating, rapid-
inactivating, and sustained inward current [28,29]. These
proton-gated currents were mediated by ASICs in the
presence of the TRPV1 inhibitor capsazepine, although we
did not identify the ASIC subunits in the present study.
Protons activated the members of the ASIC family rather
than TRPV1, since the three types of currents were
blocked by amiloride, a broad-spectrum ASIC blocker.
Therefore, these proton-gated currents were considered to






















Figure 5 Intracellular mechanisms underlying the potentiation of proton-gated currents by prokineticin 2 signaling. (A) The first line of
current traces show that PK2 still enhanced proton-gated currents after re-patch with normal internal solution on the same neuron. The second
line of current traces show the effect of intracellular dialysis of GF109203X, a PKC inhibitor, on the PK2-induced potentiation of proton-gated
currents. The third line of traces were taken from neurons treated with PICK1 inhibitor FSC-231. GF109203X (2 μM) and FSC-231 (50 μM) was
included in the recording pipette for intracellular dialysis. Proton-gated currents were elicited by application of pH 5.5 for 5 s durations. PK2 (1
nM) was pre-applied to external solution for 1 min. Arrow represents re-patch clamp and intracellular dialysis. The bar graph in (B) shows the
percentage increases in the IpH5.5 induced by PK2 (10
-9 M) with recording pipettes filled with the normal internal solution (n = 7), GF109203X
(n = 8) or FSC-231 (n = 8) containing internal solution in the second patch experiments. Intracellular dialysis of GF109203X or FSC-231 abolished
the enhancing effect of PK2 on IpH5.5. *P <0.05, **P <0.01, post hoc Bonferroni’s test, compared with normal internal solution. PICK1: protein
interacting with C-kinase 1; PK2: prokineticin 2.
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Figure 7 Effect of prokineticin 2 on nociceptive responses to injection of acetic acid in rats. Intraplantar injection acetic acid evoked a
flinch/shaking response in the presence of the TRPV1 inhibitor capsazepine (100 μM). The pretreatment of PK2 increased flinching behavior
induced by acetic acid in dose-dependent manner. The effect of PK2 was blocked by PKRA (10 nM), a PK2 receptor antagonist. Flinching or
shaking of the paw was recorded as the number of flinches per observation period (5 min). **P <0.01, post hoc Bonferroni’s test, compared with
control; #P <0.05, post hoc Bonferroni’s test, compared with PK2 (3nM) column. n = 10 per each column. PKRA: prokineticin 2 receptor antagonist;
PK2: prokineticin 2; TRPV1: transient receptor potential vanilloid receptor-1.





































Figure 6 Effect of prokineticin 2 on proton-evoked membrane excitability of rat dorsal root ganglia neurons. (A) Original current and
membrane potential recordings from the same DRG neuron. Left panel: voltage-clamp recording of current induced by a pH 6.0 acid stimulus in
the presence of the TRPV1 inhibitor capsazepine (10 μm). Holding potential was −60 mV. Right panel: current-clamp recording (I = 0 pA) of the
depolarization evoked by the pH 6.0 acid stimulus from the same neuron as the left panel in the presence of capsazepine (10 μM) to block TRPV1
and TTX (1 μM) to block Na+ channel-mediated action potentials. The pretreatment of PK2 (1 nM) enhanced the acid-induced membrane
depolarization. No action potential was triggered by the membrane depolarization in the neuron. (B) Original current and spiking recordings
from the same DRG neuron. Left panel: a pH 5.5 acid stimulus induced an inward current with voltage-clamp recording. Right panel: the pH 5.5
acid stimulus produced a cell spiking with current-clamp recording in the same neuron in the presence of the TRPV1 inhibitor capsazepine
(10 μM). The pretreatment with PK2 (1 nM) increased the acid-induced spiking activity. (C and D) Bar graphs show the effect of PK2 on
membrane potential depolarization produced by pH 6.0 and the number of spiking produced by pH 5.5. After a 20 min washout of PK2, the acid-
evoked depolarization and spiking recovered to control condition. *P <0.05, paired t-test, compared with pH alone, n = 6 in each column. DRG:
dorsal ganglia root; PK2: prokineticin 2; TRPV1: transient receptor potential vanilloid receptor-1; TTX: tetrodotoxin.
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be ASIC currents. In the present study, our results showed
that PK2 enhanced all three types of proton-induced cur-
rents, and no data indicated the existence of selectivity over
these acid currents recorded in DRG neurons. We showed
that PK2 treatment sensitized ASIC activation by shifting
the proton concentration-response curve upward and in-
creasing the maximum response without changing the
threshold value and EC50.
PKRs may mediate PK2 enhancing effect on proton-
gated currents, since the potentiation of PK2 was blocked
by PKRA, a PK2 receptor antagonist. It has been shown
that PKR1 and PKR2 are present in nociceptive primary
sensory neurons [15,17]. PKR1 is more abundant than
PKR2 and is expressed prevalently in small neurons, while
PKR2 is only expressed in a small number of medium and
large neurons. It has been shown that the PK2-PKR1 pair
may play a major role in pain perception [12,19,30]. How-
ever, the absence of selective antagonists for PKR1 and
PKR2 means that an involvement of PKR2 cannot be ruled
out in the present study. The potentiation of proton-gated
currents by PK2 may involve intracellular signal transduc-
tion, since the potentiation was blocked by intracellular
dialysis of GF-109203X, a selective PKC inhibitor [31]. In
agreement with this, we previously found that PK2 sup-
presses gamma-aminobutyric-acid -activated current via
the PKC signal pathway in rat primary sensory neurons
[32]. Deval et al. [33] demonstrated that ASIC3-like cur-
rents in cultured DRG neurons are increased by the PKC
activator, phorbol 12,13-dibutyrate, and by pain mediators
such as serotonin, which are also known to activate PKC
through their cognate G protein-coupled receptors.
Potentiation of ASIC currents by PKC requires the pres-
ence of PICK1, a PSD-95/Discs-large/ZO-1 homology
(PDZ) domain-containing protein [34,35]. ASICs contain
a PDZ-binding motif at their C termini and interact with
several PDZ-containing proteins. The associated proteins
control the surface expression, the subcellular distribution
and the function of ASICs [36]. PICK1 has been shown to
co-localize with ASICs and interact directly with the PDZ-
binding domain sequences of these channels [37,38]. The
PICK1 PDZ domain of ASICs may be involved in the po-
tentiation of proton-gated currents by PK2, since the po-
tentiation was evidently blocked by intracellular dialysis of
FSC-231, a small-molecule inhibitor of the PICK1 PDZ
domain [39].
ASICs are a family of cation channels and extracellular
pH sensors. Activation of ASICs by protons induces an in-
ward current, which in turn produces a depolarization of
the resting membrane potential and triggers bursts of ac-
tion potentials [40]. The current-clamp experiments
showed that PK2 increased acid-evoked neuronal
excitability of DRG neurons, which appeared to be related
to its enhancing effect on the ASIC current amplitude in
voltage-clamp experiments. These results are also
consistent with the PK2 enhancing effect of on acetic
acid-induced pain behavior in rats. In the presence of the
TRPV1 inhibitor capsazepine, the pain response evoked
by intraplantar injection of acetic acid solution was
blocked by the ASIC blocker amiloride, suggesting the in-
volvement of ASICs. The cutaneous acid-induced pain
appears to be largely mediated by ASICs [1,41]. Thus, the
enhancing effect of PK2 on acetic acid-induced pain be-
havior may be via ASICs rather than TRPV1. It has been
shown that deletion of the PK2 and PKR1 gene strongly
reduces acid-induced visceral pain [15,19].
The PK2 potentiation of ASICs activity is likely to be
of physiological relevance in pathologies in which both
tissue acidosis and PK2 may occur together, such as
inflammation. We used the cell body of DRG neurons
as a simple and accessible model to examine the charac-
teristics of the membrane of peripheral terminals in this
work. Histochemical analysis reveals the presence of
ASIC2 and ASIC3 in cutaneous nerve endings [9,42].
During inflammation, protons are among the first
mediators released by damaged cells, and extracellular
pH values can drop to 5.4 [43]. Tissue acidosis is a
common factor found in several other pain-generating
conditions such as ischemia, tumor development, and
skin and muscle incision following surgical procedure
[44]. Protons can depolarize the peripheral free term-
inals of nociceptive neurons, and cause pain. In this
process, ASICs play an important role although TRPVs
are also likely involved. Several reports indicate that
PK2 is released from inflammatory cells and levels are
highly increased within inflamed tissues [18,45]. PK2
causes hyperalgesia through the activation of PKRs
expressed by sensory neurons [17]. In tissue injury and
inflammation, when both protons and PK2 are present,
they could activate their cognate receptors and initiate
nociceptive process. It is likely that PK2, as a proalgesic
factor, potentiates ASIC activity.
Conclusions
Our results indicate an important regulatory role of
PK2, a new pronociceptive mediator, in nociceptive
processing. PK2 increases the activity of ASICs via PK2
receptor and PKC-dependent signal pathways in rat
primary sensory neurons. These findings support that
PK2 signaling likely contributes to acidosis-evoked pain
by sensitizing ASICs.
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